Stage 1 lung cancer means a tumor is confined to the lung and has not spread to any lymph nodes or other parts of the body. The tumor is 4 centimeters or smaller, roughly the size of a walnut or less. This is the earliest stage at which lung cancer is typically diagnosed, and it carries the most favorable outlook of any lung cancer stage, with a five-year relative survival rate of about 65.5% for localized disease overall.
How Stage 1 Is Defined by Tumor Size
Stage 1 is divided into sub-stages based on how large the tumor measures across. These distinctions matter because they influence treatment decisions and prognosis.
- Stage IA1: The tumor is 1 cm or smaller, or it has only minimally invaded deeper lung tissue (no more than 0.5 cm deep).
- Stage IA2: The tumor is larger than 1 cm but no larger than 2 cm.
- Stage IA3: The tumor is larger than 2 cm but no larger than 3 cm.
- Stage IB: The tumor is larger than 3 cm but no larger than 4 cm.
In every sub-stage, the cancer has not reached nearby lymph nodes and has not metastasized. The moment cancer appears in a lymph node, it moves to at least stage 2. These size thresholds apply to non-small cell lung cancer, which accounts for roughly 80 to 85 percent of all lung cancer diagnoses.
Why Stage 1 Often Has No Symptoms
Most people with stage 1 lung cancer feel completely fine. Early lung tumors are small enough that they rarely cause noticeable problems, which is a major reason lung cancer is so often caught at later stages instead. When symptoms do appear, they tend to be vague: a persistent cough, mild shortness of breath, or chest discomfort that gets dismissed or attributed to something else.
The most reliable way to catch lung cancer this early is through screening. A landmark U.S. trial found that screening high-risk individuals with low-dose CT scans reduced lung cancer deaths by 20% compared to standard chest X-rays. High-risk generally means current or former heavy smokers over a certain age. Many stage 1 diagnoses happen incidentally, when a CT scan is done for an unrelated reason and a small nodule turns up.
Surgery as the Primary Treatment
Surgery is the standard first-line treatment for stage 1 lung cancer. The most common procedure is a lobectomy, which removes the entire lobe of the lung containing the tumor. Each lung has multiple lobes (three on the right, two on the left), so removing one still leaves significant breathing capacity.
For tumors 2 cm or smaller, a less extensive surgery may work just as well. These smaller operations, called segmentectomy or wedge resection, remove only the portion of the lobe surrounding the tumor. Research comparing these approaches in stage IA tumors under 2 cm has found similar survival rates and recurrence rates between the smaller resection and a full lobectomy. This is significant because preserving more lung tissue means better breathing function afterward.
Recovery from lung surgery typically involves a hospital stay of several days, followed by weeks of gradually returning to normal activity. Most people notice some reduction in exercise tolerance, particularly after a lobectomy, though the body adapts over time.
Radiation as an Alternative
For patients who are healthy enough for surgery but prefer a non-surgical option, or for those who cannot undergo an operation due to other health conditions, a focused form of radiation therapy is an effective alternative. This approach delivers high doses of radiation precisely to the tumor over a small number of sessions, typically completed within one to two weeks.
A clinical trial following patients for ten years found that outcomes were remarkably similar between this type of radiation and surgery. Among 80 patients with tumors under 3 cm and no lymph node involvement, 69% of those who received radiation were alive at ten years compared to 66% of those who had surgery. Lung cancer-specific survival was 92% for the radiation group and 89% for the surgery group. Side effects were minimal, with no treatment-related hospitalizations or deaths reported.
When Additional Treatment Is Needed
Most stage 1 patients do not need chemotherapy after surgery. The tumor is small, contained, and fully removed. However, certain high-risk features can change that calculation, particularly for stage IB tumors.
One feature doctors look for is a pattern called “spread through air spaces,” where cancer cells have drifted into the air sacs surrounding the main tumor. Research has shown that stage IB patients with this pattern face a higher risk of the cancer coming back, and that chemotherapy after surgery cuts that recurrence risk roughly in half. Your surgical team will examine the removed tissue under a microscope to determine whether these features are present.
Biomarker testing is also becoming standard in early-stage lung cancer. About 71% of early-stage patients now receive testing for a mutation called EGFR, and 74% are tested for a protein called PD-L1. These results don’t always change immediate treatment, but they provide critical information if the cancer ever returns, helping doctors choose targeted therapies rather than starting from scratch.
Follow-Up After Treatment
After treatment for stage 1 lung cancer, you’ll follow a structured monitoring schedule designed to catch any recurrence as early as possible.
If you had surgery without radiation, the typical plan involves a physical exam and chest CT scan every six months for the first two to three years. If those results stay normal, the visits shift to once a year with a low-dose CT scan going forward. If your treatment was radiation-based, the schedule is more frequent at first: every three to six months for the first three years, then every six months for two more years, then annually after that.
These follow-up scans serve a dual purpose. They monitor the treated area for any sign of the original cancer returning, and they screen for entirely new lung cancers, since having had one raises the risk of developing another. Most recurrences that do happen show up within the first two to three years, which is why surveillance is most intensive during that window.
What the Survival Numbers Mean
The overall five-year relative survival rate for localized lung cancer is 65.5%, based on data from the National Cancer Institute’s SEER database covering 2016 through 2022. That number represents all localized lung cancers grouped together, including people diagnosed at various ages and with varying overall health.
Within stage 1 specifically, outcomes improve with smaller tumor size. A person with a stage IA1 tumor under 1 cm who undergoes surgery has a considerably better prognosis than someone with a 4 cm stage IB tumor. The sub-staging system exists precisely because these size differences translate into meaningfully different outcomes. Your oncologist can give you a more personalized estimate based on your tumor’s exact size, type, and molecular characteristics.